Fig. 8

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma. (A) Ang and TAT peptide are modified to EVs membrane surface to obtain engineered EVs with glioma targeting and tumor-penetrating functions. (B) Schematic illustration of EVs for in vivo delivery of Cas9 protein and sgRNA for the treatment of brain tumor. Figure reprinted from Liu et al. [168] with permission under the Creative Commons CC BY-NC-ND 4.0 license. © 2023 The Authors. Published by American Chemical Society. (https://creativecommons.org/licenses/by-nc-nd/4.0/)